4 Ways AstraZeneca plc Will Continue To Lead The Biotechnology Sector

How does AstraZeneca plc (LON: AZN) compare to its sector peers?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m comparing some of the most popular companies in the FTSE 100 with their sector peers in an attempt to establish which one is the more attractive investment.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US)

Valuation

First off, let’s take a look at AstraZeneca’s valuation in relation to its sector peers. AstraZeneca currently trades at a historic P/E ratio of 7.9, below the biotechnology sector average of 17.1.

Should you invest £1,000 in BP right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BP made the list?

See the 6 stocks

However, as the company is set to lose the exclusive manufacturing rights to a number of treatments during the next few years, City analysts expect AstraZeneca’s earnings to fall next year. As a result, AstraZeneca’s forward P/E ratio is 9.9 — still lower than its sector peers. 

Balance sheet

  Net-debt-to-assets Interest cover by operating profit
AstraZeneca 5% 18x
GlaxoSmithKline 34% 10x
Shire 5%

Although AstraZeneca’s earnings are expected to decline during the next few years, the company is well placed to ride out this trend.

Indeed, AstraZeneca’s balance sheet is strong and net debt only amounts to 5% of assets. What’s more, AstraZeneca is able to cover its interest costs 18 times by operating profit.

This solid financial position has given AstraZeneca a great spring-board for the company to be able to acquire peers and treatments to bolster its flagging pipeline.

In particular, since October last year AstraZeneca has acquired five smaller peers, signed five collaboration deals and commenced two licence deals. Half of these deals are related to cancer treatments.

Company’s performance

  Earnings growth past five years Net profit margin
AstraZeneca 26% 14%
GlaxoSmithKline 8% 16%
Shire 317% 13%

Moreover, AstraZeneca’s earnings have expanded faster than those of that of close peer GlaxoSmithKline during the past five years. That said, AstraZeneca’s net profit margin, which currently sits at 14%, is down from its five-year high of 30% seen back in 2011.

Still, AstraZeneca’s recent acquisitions and collaborations show that management is working hard to drive the company’s growth and profitability back to historic levels. 

Dividends

  Current Dividend Yield Current dividend cover Projected annual dividend growth for next two years.
AstraZeneca 5.5% 2.3 2%
GlaxoSmithKline 4.7% 1.5 6%
Shire 0.4% 7.7 38%
Sector average 4.5% 1.3  

Furthermore, AstraZeneca currently offers the largest dividend yield out of its close peers. Having said that, City analysts expect AstraZeneca’s payout to expand only 4% over the next two years.

Nonetheless, AstraZeneca’s payout is covered more than twice by earnings, which gives me confidence that the payout will be maintained even if earnings fall. 

Foolish summary

All in all, AstraZeneca is currently trading at a low valuation in relation to peers, has a clean balance sheet and is working hard to drive growth.

So overall, I feel that AstraZeneca is a much stronger share than its peers. 

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

I’m trying to follow Warren Buffett’s advice with this FTSE 100 stock

As Warren Buffett steps aside at Berkshire Hathaway, Stephen Wright is thinking about how to put his investing principles into…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I bought 3,254 Taylor Wimpey shares 2 years ago – here’s how much income they’ve paid since

Harvey Jones says his investment in Taylor Wimpey shares hasn't delivered much growth so far but the dividends are now…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Here’s why I started a pension (SIPP) for my 1-year-old

The SIPP gives Britons more control over their pensions. Dr James Fox explains why parents should consider opening SIPPs for…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

£20K of savings? Here’s how it could fuel a £633 monthly second income

Christopher Ruane outlines some practical steps a stock market newbie could take to building a sizeable second income from dividend…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

2 shares to consider as a new US deal could revive the UK stock market

Our writer investigates two major FTSE 100 shares that could enjoy a boost following a US tariff shift and possible…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

This FTSE 250 growth trust just loaded up on these 2 top S&P 500 stocks

Our writer noticed that this FTSE 250 investment trust has just scooped up a couple of quality US growth stocks.…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

This world-class FTSE 100 company’s expecting up to 10% growth in 2025

This is one of the most profitable companies in the FTSE 100 index. And right now, it’s firing on all…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10k invested in Phoenix shares 10 years ago would have generated passive income of…  

Shares in this FTSE 100 insurance giant have done poorly over the last decade. Harvey Jones wonders if super-sized passive…

Read more »